Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of TAK-020 in Healthy Volunteers
NCT02413255Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-020 in hematologic malignancy and autoimmune diseases (17 arms), sponsored by Takeda. Primary endpoints: Treatment-emergent Adverse Events, Markedly Abnormal Values for Safety Laboratory Findings and 2 more. Started Mar 2015; status: completed.
02
Drugs
TAK-020
03
Conditions
hematologic malignancyautoimmune diseases
Beyond the preview
Go deeper on NCT02413255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413255.